Amedisys (NASDAQ:AMED) PT Lowered to $154.00 at Barclays

Amedisys (NASDAQ:AMEDGet Rating) had its price target trimmed by Barclays from $181.00 to $154.00 in a report issued on Friday morning, The Fly reports. They currently have a maintains rating on the health services provider’s stock.

AMED has been the topic of a number of other reports. SVB Leerink lowered their price objective on Amedisys from $117.00 to $107.00 and set a market perform rating on the stock in a research report on Tuesday, June 21st. Stifel Nicolaus initiated coverage on Amedisys in a research report on Tuesday, June 28th. They set a hold rating and a $128.00 price objective on the stock. Raymond James lowered their price target on Amedisys from $200.00 to $180.00 in a research report on Friday, April 29th. Bank of America cut Amedisys from a neutral rating to an underperform rating and lowered their price target for the company from $145.00 to $102.00 in a research report on Tuesday, June 21st. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Amedisys from $210.00 to $175.00 and set a buy rating on the stock in a research report on Tuesday, June 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and an average target price of $160.88.

Amedisys Stock Down 1.8 %

Shares of AMED stock opened at $119.85 on Friday. Amedisys has a 12 month low of $101.61 and a 12 month high of $264.10. The firm has a market cap of $3.90 billion, a PE ratio of 20.63, a price-to-earnings-growth ratio of 2.48 and a beta of 0.90. The stock has a 50 day moving average of $117.81 and a 200-day moving average of $135.30. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.42.

Amedisys (NASDAQ:AMEDGet Rating) last issued its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.24. The company had revenue of $557.89 million during the quarter, compared to analyst estimates of $583.12 million. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.69 earnings per share. On average, equities analysts predict that Amedisys will post 5.29 EPS for the current year.

Insider Activity

In other news, insider Denise M. Bohnert sold 557 shares of the company’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total transaction of $64,055.00. Following the transaction, the insider now owns 11,850 shares of the company’s stock, valued at $1,362,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amedisys

Several hedge funds have recently added to or reduced their stakes in AMED. Kestra Advisory Services LLC lifted its stake in Amedisys by 13.3% in the fourth quarter. Kestra Advisory Services LLC now owns 2,032 shares of the health services provider’s stock valued at $329,000 after buying an additional 239 shares during the period. Van ECK Associates Corp increased its holdings in shares of Amedisys by 13.6% in the fourth quarter. Van ECK Associates Corp now owns 775 shares of the health services provider’s stock worth $125,000 after acquiring an additional 93 shares in the last quarter. NN Investment Partners Holdings N.V. increased its holdings in shares of Amedisys by 10.5% in the fourth quarter. NN Investment Partners Holdings N.V. now owns 9,095 shares of the health services provider’s stock worth $1,473,000 after acquiring an additional 866 shares in the last quarter. State of Michigan Retirement System increased its holdings in shares of Amedisys by 1.2% in the fourth quarter. State of Michigan Retirement System now owns 8,251 shares of the health services provider’s stock worth $1,336,000 after acquiring an additional 100 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Amedisys in the fourth quarter worth about $85,286,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

About Amedisys

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Want More Great Investing Ideas?

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.